The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.

This research study looks to enroll as many people diagnosed with lung cancer at 45 years old or younger in order to:

• Better understand causes of lung cancer in individuals 45 years old and younger, which is a rare disease
• Better estimate lung cancer risks and potential risk factors for lung cancer in individuals 45 years old and younger
• Examine tumor (somatic) or normal (germline) genetic changes that may be shared among young lung cancer patients
• Improve opportunities for screening and treatment of lung cancer in individuals 45 years old and younger

Study procedures will include:

• Collecting information from participants' medical record and two (2) short questionnaires
• Collecting blood and/or saliva samples
• Collecting tumor tissue samples (optional)

It is expected that about 500 people will take part in this research study. Participants will be in this study until it closes or the participant withdraws consent.

Inclusion Criteria:

• Age 45 and under at lung cancer diagnosis
• Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point
• Provision of written informed consent
• Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks
• Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent

Exclusion Criteria:

• Individuals who decline to sign consent
• Individuals who are unable to give consent or assent and are without a designated healthcare proxy
• Compromise of patient diagnosis or staging if tissue is used for research

Adults age 45 or under at time of non-small lung cancer (NSCLC) or small cell lung cancer (SCLC) diagnosis

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Data can be shared no earlier than 1 year following the date of publication

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu